U.S. Food and Drug Administration Approves Brentuximab Vedotin (ADCETRIS) for Frontline Treatment of Peripheral T-Cell Lymphoma (PTCL)
New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination with chemotherapy for adult patients with previously untreated systemic anaplastic large cell lymphoma (ALCL) and…